Has Jeffrey Dover, MD received payments from drug or device companies?

Yes. Drug and device makers reported $200,025 in general payments to Jeffrey Dover, MD across 88 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Dover, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Dover, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Dover, MD

Dermatology · Chestnut Hill, MANPI 1316909005

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $175,892 of the $200,025 with a category attached, or 87.9%. Solta Medical, A Division Of Bausch Health US, LLC accounts for 81.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $70,557 and has fallen 60.1% since, to $28,154 in 2025. Among dermatology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$200,025in general payments, 2019–2025

Across 88 payments — averaging $2273.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Solta Medical, A Division Of Bausch Health US, LLC$163K
AbbVie$32K
Revance Therapeutics, Inc.$3K
Galderma Laboratories, L.p.$2K
LEO Pharma Inc.$101
Astellas Pharma US Inc$100
plus $157 from 5 others

$1,514,027in research payments, 2019–2025

Across 92 payments — averaging $16,457 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1.3M
Bausch Health US, LLC$175K
Merz North America, Inc.$76K

What the payments were for

Consulting fees$175,89288%
Speaking & faculty fees$19,90510%
Travel & lodging$2,6391%
Food & beverage$1,4631%
Education$1260%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Solta Medical, A Division Of Bausch Health US, LLC	38	$162,924
AbbVie(2 entities)	27	$31,683
Revance Therapeutics, Inc.	5	$2,631
Galderma Laboratories, L.p.	6	$2,429
LEO Pharma Inc.	4	$101
Astellas Pharma US Inc	1	$100
Novartis	2	$55
Sanofi	2	$46
Amgen	1	$25
Sun Pharmaceutical Industries Inc.	1	$16
Lilly USA, LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,025 in reported general payments places this provider in the 95th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$173,218

Medicare patients

545

Services billed

3,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	14	$52,577
SeysaraSarecycline Hcl	12	$12,166
Clobetasol Propionate	30	$1,705
Metronidazole	16	$1,451
Betamethasone Dipropionate	11	$925
Ketoconazole	47	$713
Triamcinolone Acetonide	30	$436
Doxycycline Hyclate	14	$153
ValacyclovirValacyclovir Hcl	18	$82
Minoxidil	11	$66

Paid to pharmacies, not to this prescriber.

Other dermatology in Chestnut Hill

Michael KaminerChestnut Hill$1.1M
Jeffrey SobellChestnut Hill$986K
Brooke SikoraChestnut Hill$23K
John HarrisWorcester$15M
Ethan LernerCharlestown$1.7M
Erik DominguesFall River$736K
Alexandra KimballBoston$680K
Arash MostaghimiBoston$591K
David GreensteinBeverly$540K
Brian HiblerBoston$498K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →